1st IBDHorizons Gulf Coast Symposium

In collaboration with GI Alliance, IBDHorizons Presents its First Gulf Coast Symposium in New Orleans, LA, with Co-Chairs Dr. Casey Chapman and Dr. Tim Ritter.

IBDHorizons provides free IBD conferences open to all those who treat IBD, desire to treat IBD, and who face IBD.

At our 1st Annual Gulf Coast IBD Conference, you will learn from and engage in discourse about the latest in Inflammatory Bowel Disease (IBD) from world-renowned faculty, on Saturday, October 15, 2022.

During the IBDHorizons Gulf Coast Symposium, you’ll be provided with a smooth experience including catered meals, thoughtful breaks throughout the day’s events, and a personal tablet to engage with the presentations. We dedicate more time than most other IBD education conferences to our open panel discussions and real-world case studies to be examined alongside the faculty.

Our IBD conference will be hosted at Omni Royal Orleans, 621 St Louis St, New Orleans, LA. See below table for the schedule of the day’s breakdown list of topics and faculty.

CME/CE/CPE

This IBDHorizons event will be accredited for up to 6 CME, CE, and CPE credit hours for attendees.

Cost

Registration is required to plan accordingly, but registration for IBDHorizons New Orleans is complimentary to attendees!

Lodging

If you are not local to Omni Royal Orleans Hotel, accommodations are available at a discounted rate, limited availability. The booking link is available after registering or by contacting us.

Parking

Limited valet parking is available on-site at the Omni Royal Orleans Hotel,’s garage, located on Chartres Street. The hotel is located on the corner of St. Louis and Chartres Street. If utilizing valet parking, please bring the ticket to the event registration desk to receive a stamp for a discounted event parking rate of $15 (cash only).

If the lot is full, self-parking will need to be found nearby. The lot across the street (535 Chartres St) offers self-parking. More info for this lot can be found at https://www.premiumparking.com/P149

Join us for this amazing IBD conference opportunity to engage with key/known/notable leaders in the field of Inflammatory Bowel Disease (IBD).

Virtual Attendance

We strive to be inclusive to all of the IBD community for our IBDHorizons conferences. While we prefer to have attendees in person, we understand the need for virtual attendance to our sessions. Please register at this event link and a secured link will be emailed to you on October 15th.


  • Accreditation:

    1st IBDHorizons Gulf Coast Symposium

    Course Information
    1 day - multiplatform meeting for in-person & virtual participation covering Louisiana and the surrounding region with an estimated 200 attendees. An exclusively virtual conference platform will be offered if an in-person meeting cannot be safely conducted.

    Intended Audience
    This activity was developed for healthcare providers caring for IBD patients, including gastroenterologists, surgeons, gastroenterology nurses, advanced nurse practitioners, physician assistants, and pharmacists.

    Learning Objectives
    At the conclusion of this learning activity, participants will do the following:

    1. Recognize the particular challenges related to fertility, pregnancy, prenatal and postnatal care in IBD and review the latest recommendations.
    2. Describe the comparative efficacy of the currently available therapies and the rationale for optimal positioning of these agents in IBD today.
    3. Recognize the various medical and surgical challenges for patients who receive an ileoanal pouch and the latest management recommendations.
    4. Assess the latest evidence regarding the role of therapeutic drug monitoring, proactive and reactive, to optimize response to biologic therapy in patients with IBD.
    5. Describe the clinical presentation of Crohn’s disease patients with strictures and discuss the best management for strictures including surgical intervention, endoscopic management and medical treatments.
    6. Recognize the postoperative clinical course for IBD patients who undergo surgery and review the medical and surgical challenges and their optimal management.
    7. Apply up-to-date practice in managing dysplasia in IBD from detection to endoscopic and surgical intervention.
    8. Discuss the newly approved and soon to be approved biologic and non-biologic therapies for IBD, including the risks, efficacy, and special considerations when utilizing these therapies.

     

    Accreditation and Certification

    In support of improving patient care, this activity has been planned and implemented by the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) and IBDHorizons. The Annenberg Center for Health Sciences at Eisenhower is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physicians
    The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurses
    The Annenberg Center designates this live activity for a maximum of 6.0 American Nurses Credentialing Center (ANCC) contact hour, which includes 1.50 hours of pharmacology credit.

    Pharmacists

    This activity is designated for up to 6.0 contact hours (0.6 CEUs) of continuing pharmacy credit. Credit will be provided to the NABP CPE Monitor within 60 days after the activity completion.

    Disclosure Statement
    All individuals in control of the content of continuing education activities provided by the Annenberg Center are required to disclose to the audience all relevant financial relationships related to the content of the activity. Full disclosure of all relevant financial relationships will be made in writing to the audience prior to the activity.

    The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

    All staff at the Annenberg Center for Health Sciences at Eisenhower and IBDHorizons have no relationships to disclose.

    All of the relevant financial relationships listed for these individuals have been mitigated.

    This activity is supported by educational grants from AbbVie, Bristol Myers Squibb, Ferring Pharmaceuticals, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Takeda Pharmaceuticals USA, Inc.

    IBDHorizons Privacy Policy
    https://ibdhorizons.com/privacy-policy/

    Annenberg Center for Health Sciences Privacy Policy
    Annenberg Center for Health Sciences Privacy Policy: Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at https://annenberg.net/pages/privacyPolicy.php

  • Disclosure Statements: https://ibdhorizons.com/wp-content/uploads/2022/10/Disclosure-Statements_Gulf-Coast.pdf

Hourly Schedule

Morning Session

8:00 - 8:15
Welcome & Introduction
Speakers:
Anita Afzali, MD, MPH, MHCM
8:15 - 9:00
Women's Health in IBD and The Parenthood Project
Speakers:
Rajeev Jain, MD
9:00 - 9:45
Update on Positioning Therapies and Comparative Efficacy
Speakers:
Scott Lee
9:45 - 10:15
Break
10:15 - 11:00
Advances in J-Pouch Management
Speakers:
Feza Remzi, MD
11:00 - 11:45
State of the Art in Disease and Therapeutic Monitoring
Speakers:
Anita Afzali, MD, MPH, MHCM
11:45 - 12:30
Lunch

Afternoon Session

12:30 - 1:00
Fibrostenotic Crohn's Disease: Present and Future
Speakers:
Tina Ha, MD
1:00 - 1:45
Postoperative Disease Management in IBD
Speakers:
Gary Lichtenstein, MD
1:45 - 2:30
Cancer Risk and Dysplasia Screening in IBD
Speakers:
Bincy Abraham, MD
2:30 - 3:15
Novel Pathways and Upcoming New IBD Therapies
Speakers:
Brian Feagan, MD, MSc
3:15 - 3:30
Closing
Anita Afzali, MD, MPH, MHCM
Anita Afzali, MD, MPH, MHCM
Professor of Clinical Medicine, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System and Cincinnati Children's Hospital
Dr. Anita Afzali is a Professor of Clinical Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. Dr. Afzali is also the Associate Chief Medical Officer of the UC Health System and Cincinnati Children's Hospital. She remains an Adjunct Professor of Medicine at OSU. Dr. Afzali holds the Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease. She received her medical degree and then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and also graduated with a Master’s in Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty. While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics at The Ohio State University. Her research interests include clinical outcomes and association of bowel and joint disease, the influence of the metabolic syndrome and impact of race/ethnicity in IBD, as well as pharmacoeconomics, pediatric-to-adult transition, and women of childbearing age with IBD. She is also extensively involved in IBD clinical trials for investigational therapies. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Co-Chair of the Crohn’s & Colitis National Professional Education Committee and Member of the ACG Minority Affairs and Cultural Diversity Committee.
Rajeev Jain, MD
Rajeev Jain, MD
Board Certified Gastroenterologist, Chief of Gastroenterology, Texas Digestive Disease Consultants
I choose to specialize in gastroenterology as this specialty blends the needs for diagnostic reasoning with procedural interventions across a broad variety of symptoms and disorders. I am interested in colon cancer screenings, heartburn, Barrett’s esophagus, and inflammatory bowel disease. Studied at: Undergrad: University of Texas at Austin, Medical School: Baylor College of Medicine, Residency in Internal Medicine and Fellowship in Gastroenterology: University of Texas Southwestern Medical School. Certifications Held: Board Certified in Gastroenterology. I am a Fellow of the American College of Physicians, American Gastroenterological Association, and American Society of Gastrointestinal Endoscopy. I have been named annually to D Magazine “Best Doctors” in Dallas since 2001. In 2002, I was appointed as Chief of Gastroenterology at Texas Health Presbyterian Hospital. Since 2006, I have been annually named a Texas Monthly Super Doctor. I received the Presbyterian Hospital House Staff Annual Robert L. North, M.D. Teaching Award for 2002-2003. In December 2012, I was presented the Outstanding Contribution in the Field of Medicine award by the Greater Dallas Indo-American Chamber of Commerce. I served on the Texas Society for Gastrointestinal Endoscopy as a Councilor from 2013-2015. I serve on the Governing Board of the American Gastroenterological Association as Clinical Practice Councillor from 2015-2017, as well as on the Board of Directors for the American Board of Internal Medicine from 2016-2018.
Scott Lee
Scott Lee
Associate Professor of Medicine
Dr. Lee is an associate professor of medicine with expertise in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Dr. Lee earned his bachelor’s degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center. Currently his clinical practice is at the Digestive Disease Center at the University of Washington and is dedicated exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program. He is a member of the Crohn’s Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology and American Society of Gastrointestinal Endoscopy. He is a past chair of Northwest CCFA Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.
Feza Remzi, MD
Feza Remzi, MD
Colorectal Surgeon at NYU Langone, Director of IBD Center, Professor of Surgery at NYU School of Medicine
As a colorectal surgeon at NYU Langone, Dr. Remzi is a foremost expert in the surgical management of Inflammatory Bowel Disease, also known as Crohn’s Disease and Ulcerative Colitis. Dr. Remzi performs pelvic pouch surgery and complex abdominopelvic re-operative surgery, as well as sphincter-saving surgery for rectal cancer, applying minimally invasive techniques to manage colorectal conditions. Dr. Remzi serves as the director of the Inflammatory Bowel Disease Center and is one of the few colorectal surgeons in the world who is specialized in caring for people who are experiencing problems with a prior pelvic pouch, or J-pouch, procedures. He states "I have been humbled and privileged to be able to help my patients for more than 20 years. I treat my patients the way I would treat my own family. I take a team approach to care, so we bring together medical, surgical, and nursing professionals who devote 100 percent of their efforts to giving patients a better chance at life. Many of the people I treat are experiencing complex problems that impact not only their own quality of life but also that of their families. Therefore, I include patients’ family members as a part of the treatment team." As a national and international expert in colorectal surgery, Dr. Remzi has published many articles and book chapters on the surgical management of Inflammatory Bowel Disease, ileal J-pouch surgery, and re-operative abdominopelvic surgery. He is an honored member of the American Surgical Association and is humbled to be one of only a handful of surgeons in the world who is a member of the International Organization For the Study of Inflammatory Bowel Disease.
Tina Ha, MD
Tina Ha, MD
Director, Inflammatory Bowel Diseases Section, Mayo Clinic Arizona
Dr. Tina Ha is a gastroenterologist in Scottsdale, Arizona. She is affiliated with multiple hospitals, including Mayo Clinic- Phoenix, where she is the Director of the Inflammatory Bowel Diseases Section, and Cedars-Sinai Medical Center. Dr. Ha earned her medical degree from the Albert Einstein College of Medicine of Yeshiva University. She did an internal medicine residency at Washington University in St. Louis School of Medicine as well as a fellowship in gastroenterology. She continued to a fellowship in inflammatory bowel disease at the Icahn School of Medicine at Mount Sinai. She likes to spend her free time exploring with her golden retriever Sebastian, - who does not enjoy walking or retrieving, friends and family. Dr. Ha has contributed to many publications on the topic of IBD.
Gary Lichtenstein, MD
Gary Lichtenstein, MD
Director, Inflammatory Bowel Disease Center, Professor of Medicine, University of Pennsylvania
Gary R. Lichtenstein, MD, FACP, FACG, AGAF is the Director of the Inflammatory Bowel Disease Center and a Professor of Medicine in the Gastrointestinal Division of the Department of Medicine at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine, in New York, New York. He then completed his internship and residency in Internal Medicine at Duke University Medical Center, in Durham, North Carolina. He also served a fellowship in Gastroenterology at the Hospital of the University of Pennsylvania of the University Of Pennsylvania School Of Medicine. His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn's disease. Dr. Lichtenstein has received numerous research grants focusing on these areas and has served as the national/ international principal investigator evaluating novel agents for therapeutic trials in the treatment of Ulcerative Colitis and Crohn's disease.
Bincy Abraham, MD
Bincy Abraham, MD
Director, Fondren IBD Program, Director, Gastroenterology Fellowship Program Underwood Center for Digestive Disorders, Houston Methodist Hospital
Bincy P Abraham, MD, MS, AGAF, FACG is the Distinguished Professor and Director of the Fondren Inflammatory Bowel Disease Program at the Underwood Digestive Diseases Center of Houston Methodist Hospital. She is also the Program Director for the Gastroenterology Fellowship at Houston Methodist Hospital. Dr. Abraham earned her undergraduate degree in bioengineering at Texas A&M University in College Station, and then received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston. She completed her internal medicine internship and residency, as well as a gastroenterology fellowship at UTMB, where she also earned a master’s in clinical investigation and received specialized training in inflammatory bowel disease (IBD). During her training, she completed a National Visiting Fellow IBD Rotation Program through the Crohn’s and Colitis Foundation of America at Cedars-Sinai Medical Center in Los Angeles, California. After fellowship, she joined as faculty as assistant professor of medicine in the section of Gastroenterology and Hepatology at Baylor College of Medicine where she served as director of the Baylor Clinic Inflammatory Bowel Disease Center for over 5 years before her move to Houston Methodist Hospital. She is board-certified in Internal medicine and Gastroenterology. Her particular interest in inflammatory bowel disease includes the transition of adolescent IBD patients from pediatric to adult care as well as women’s issues and pregnancy in IBD. She chairs the Southern Regional Chapter of the CCFA Medical Advisory Committee, has served as president of the Texas Gulf Coast Gastroenterology Society, co-directed the Texas Society of Gastroenterology & Endoscopy Annual meeting, is involved in national committees for American College of Gastroenterology, and member of American Gastroenterology Association, and Crohn's and Colitis Foundation.
Brian Feagan, MD, MSc
Brian Feagan, MD, MSc
Professor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc
Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Crohn’s disease (CD) and ulcerative colitis (UC), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in CD and UC. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc). Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).

Date

Oct 15 2022

Time

8:00 am - 3:30 pm

Location

Omni Royal Orleans Hotel
New Orleans, LA

Speakers

  • Anita Afzali, MD, MPH, MHCM
    Anita Afzali, MD, MPH, MHCM
    Professor of Clinical Medicine, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System and Cincinnati Children's Hospital

    Dr. Anita Afzali is a Professor of Clinical Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. Dr. Afzali is also the Associate Chief Medical Officer of the UC Health System and Cincinnati Children’s Hospital.

    She remains an Adjunct Professor of Medicine at OSU.
    Dr. Afzali holds the Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease. She received her medical degree and then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and also graduated with a Master’s in Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty. While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics at The Ohio State University.
    Her research interests include clinical outcomes and association of bowel and joint disease, the influence of the metabolic syndrome and impact of race/ethnicity in IBD, as well as pharmacoeconomics, pediatric-to-adult transition, and women of childbearing age with IBD. She is also extensively involved in IBD clinical trials for investigational therapies. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Co-Chair of the Crohn’s & Colitis National Professional Education Committee and Member of the ACG Minority Affairs and Cultural Diversity Committee.

  • Bincy Abraham, MD
    Bincy Abraham, MD
    Director, Fondren IBD Program, Director, Gastroenterology Fellowship Program Underwood Center for Digestive Disorders, Houston Methodist Hospital

    Bincy P Abraham, MD, MS, AGAF, FACG is the Distinguished Professor and Director of the Fondren Inflammatory Bowel Disease Program at the Underwood Digestive Diseases Center of Houston Methodist Hospital. She is also the Program Director for the Gastroenterology Fellowship at Houston Methodist Hospital.

    Dr. Abraham earned her undergraduate degree in bioengineering at Texas A&M University in College Station, and then received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston. She completed her internal medicine internship and residency, as well as a gastroenterology fellowship at UTMB, where she also earned a master’s in clinical investigation and received specialized training in inflammatory bowel disease (IBD). During her training, she completed a National Visiting Fellow IBD Rotation Program through the Crohn’s and Colitis Foundation of America at Cedars-Sinai Medical Center in Los Angeles, California. After fellowship, she joined as faculty as assistant professor of medicine in the section of Gastroenterology and Hepatology at Baylor College of Medicine where she served as director of the Baylor Clinic Inflammatory Bowel Disease Center for over 5 years before her move to Houston Methodist Hospital. She is board-certified in Internal medicine and Gastroenterology.

    Her particular interest in inflammatory bowel disease includes the transition of adolescent IBD patients from pediatric to adult care as well as women’s issues and pregnancy in IBD. She chairs the Southern Regional Chapter of the CCFA Medical Advisory Committee, has served as president of the Texas Gulf Coast Gastroenterology Society, co-directed the Texas Society of Gastroenterology & Endoscopy Annual meeting, is involved in national committees for American College of Gastroenterology, and member of American Gastroenterology Association, and Crohn’s and Colitis Foundation.

  • Brian Feagan, MD, MSc
    Brian Feagan, MD, MSc
    Professor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc

    Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Crohn’s disease (CD) and ulcerative colitis (UC), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in CD and UC. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc).

    Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).

  • Casey Chapman
    Casey Chapman
    Chief Medical Officer, GI Alliancee

    Dr. Casey Chapman is the Chief Medical Officer for GI Alliance. He is an actively practicing gastroenterologist in Baton Rouge, LA, focusing on Inflammatory Bowel Disease.

    Dr. Chapman earned his medical degree from Louisiana State University School of Medicine. He completed his residency and fellowship at LSU Health Science Center.

  • Feza Remzi, MD
    Feza Remzi, MD
    Colorectal Surgeon at NYU Langone, Director of IBD Center, Professor of Surgery at NYU School of Medicine

    As a colorectal surgeon at NYU Langone, Dr. Remzi is a foremost expert in the surgical management of Inflammatory Bowel Disease, also known as Crohn’s Disease and Ulcerative Colitis. Dr. Remzi performs pelvic pouch surgery and complex abdominopelvic re-operative surgery, as well as sphincter-saving surgery for rectal cancer, applying minimally invasive techniques to manage colorectal conditions.
    Dr. Remzi serves as the director of the Inflammatory Bowel Disease Center and is one of the few colorectal surgeons in the world who is specialized in caring for people who are experiencing problems with a prior pelvic pouch, or J-pouch, procedures. He states “I have been humbled and privileged to be able to help my patients for more than 20 years. I treat my patients the way I would treat my own family. I take a team approach to care, so we bring together medical, surgical, and nursing professionals who devote 100 percent of their efforts to giving patients a better chance at life. Many of the people I treat are experiencing complex problems that impact not only their own quality of life but also that of their families. Therefore, I include patients’ family members as a part of the treatment team.”
    As a national and international expert in colorectal surgery, Dr. Remzi has published many articles and book chapters on the surgical management of Inflammatory Bowel Disease, ileal J-pouch surgery, and re-operative abdominopelvic surgery. He is an honored member of the American Surgical Association and is humbled to be one of only a handful of surgeons in the world who is a member of the International Organization For the Study of Inflammatory Bowel Disease.

  • Gary Lichtenstein, MD
    Gary Lichtenstein, MD
    Director, Inflammatory Bowel Disease Center, Professor of Medicine, University of Pennsylvania

    Gary R. Lichtenstein, MD, FACP, FACG, AGAF is the Director of the Inflammatory Bowel Disease Center and a Professor of Medicine in the Gastrointestinal Division of the Department of Medicine at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania.

    Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine, in New York, New York. He then completed his internship and residency in Internal Medicine at Duke University Medical Center, in Durham, North Carolina. He also served a fellowship in Gastroenterology at the Hospital of the University of Pennsylvania of the University Of Pennsylvania School Of Medicine. His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn’s disease. Dr. Lichtenstein has received numerous research grants focusing on these areas and has served as the national/ international principal investigator evaluating novel agents for therapeutic trials in the treatment of Ulcerative Colitis and Crohn’s disease.

  • Rajeev Jain, MD
    Rajeev Jain, MD
    Board Certified Gastroenterologist, Chief of Gastroenterology, Texas Digestive Disease Consultants

    I choose to specialize in gastroenterology as this specialty blends the needs for diagnostic reasoning with procedural interventions across a broad variety of symptoms and disorders.

    I am interested in colon cancer screenings, heartburn, Barrett’s esophagus, and inflammatory bowel disease.

    Studied at:
    Undergrad: University of Texas at Austin,
    Medical School: Baylor College of Medicine,
    Residency in Internal Medicine and Fellowship in Gastroenterology: University of Texas Southwestern Medical School.

    Certifications Held:
    Board Certified in Gastroenterology. I am a Fellow of the American College of Physicians, American Gastroenterological Association, and American Society of Gastrointestinal Endoscopy.

    I have been named annually to D Magazine “Best Doctors” in Dallas since 2001. In 2002, I was appointed as Chief of Gastroenterology at Texas Health Presbyterian Hospital. Since 2006, I have been annually named a Texas Monthly Super Doctor. I received the Presbyterian Hospital House Staff Annual Robert L. North, M.D. Teaching Award for 2002-2003. In December 2012, I was presented the Outstanding Contribution in the Field of Medicine award by the Greater Dallas Indo-American Chamber of Commerce. I served on the Texas Society for Gastrointestinal Endoscopy as a Councilor from 2013-2015. I serve on the Governing Board of the American Gastroenterological Association as Clinical Practice Councillor from 2015-2017, as well as on the Board of Directors for the American Board of Internal Medicine from 2016-2018.

  • Scott D. Lee MD
    Scott D. Lee MD
    Associate Professor of Medicine, Director, Clinical Inflammatory Bowel Disease Program at University of Washington Medical Center

    Dr. Scott D. Lee is an associate professor of medicine with expertise in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Dr. Lee earned his bachelor’s degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center. Currently, his clinical practice is at the Digestive Disease Center at the University of Washington and is dedicated exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long-term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients, and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program. He is a member of the Crohn’s Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology, and American Society of Gastrointestinal Endoscopy. He is a past chair of Northwest CCFA Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.

  • Tim Ritter
    Tim Ritter
    Senior Medical Director

    Dr. Timothy Ritter is Senior Medical Director of the Department of Research and Education at GI Alliance. His interest within GI is Inflammatory Bowel Disease and Clinical Trials.

    He is a practicing gastroenterologist in Southlake, Texas and an Assistant Professor of Medicine at TCU School of Medicine.

    Dr. Ritter earned his medical degree from the University of Texas Southwestern, where he also completed his residency and fellowship. He was awarded a Regional Top Doctor in 2014 by Castle Connolly and is a professional member of the American Gastroenterological Association, the American College of Gastroenterology, the Texas Society for Gastroenterology & Endoscopy, and the American Society for Gastrointestinal Endoscopy.

  • Tina Ha, MD
    Tina Ha, MD
    Director, Inflammatory Bowel Diseases Section, Mayo Clinic Arizona

    Dr. Tina Ha is a gastroenterologist in Scottsdale, Arizona. She is affiliated with multiple hospitals, including Mayo Clinic- Phoenix, where she is the Director of the Inflammatory Bowel Diseases Section, and Cedars-Sinai Medical Center.

    Dr. Ha earned her medical degree from the Albert Einstein College of Medicine of Yeshiva University. She did an internal medicine residency at Washington University in St. Louis School of Medicine as well as a fellowship in gastroenterology. She continued to a fellowship in inflammatory bowel disease at the Icahn School of Medicine at Mount Sinai.

    She likes to spend her free time exploring with her golden retriever Sebastian, – who does not enjoy walking or retrieving, friends and family.

    Dr. Ha has contributed to many publications on the topic of IBD.

QR Code

Hourly Schedule

Morning Session

8:00 - 8:15
Welcome & Introduction
Speakers:
Anita Afzali, MD, MPH, MHCM
8:15 - 9:00
Women's Health in IBD and The Parenthood Project
Speakers:
Rajeev Jain, MD
9:00 - 9:45
Update on Positioning Therapies and Comparative Efficacy
Speakers:
Scott Lee
9:45 - 10:15
Break
10:15 - 11:00
Advances in J-Pouch Management
Speakers:
Feza Remzi, MD
11:00 - 11:45
State of the Art in Disease and Therapeutic Monitoring
Speakers:
Anita Afzali, MD, MPH, MHCM
11:45 - 12:30
Lunch

Afternoon Session

12:30 - 1:00
Fibrostenotic Crohn's Disease: Present and Future
Speakers:
Tina Ha, MD
1:00 - 1:45
Postoperative Disease Management in IBD
Speakers:
Gary Lichtenstein, MD
1:45 - 2:30
Cancer Risk and Dysplasia Screening in IBD
Speakers:
Bincy Abraham, MD
2:30 - 3:15
Novel Pathways and Upcoming New IBD Therapies
Speakers:
Brian Feagan, MD, MSc
3:15 - 3:30
Closing
Anita Afzali, MD, MPH, MHCM
Anita Afzali, MD, MPH, MHCM
Professor of Clinical Medicine, Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine, Associate Chief Medical Officer of the UC Health System and Cincinnati Children's Hospital
Dr. Anita Afzali is a Professor of Clinical Medicine in the Division of Digestive Diseases and Executive Vice Chair of Medicine in the Department of Internal Medicine at the University of Cincinnati College of Medicine. Dr. Afzali is also the Associate Chief Medical Officer of the UC Health System and Cincinnati Children's Hospital. She remains an Adjunct Professor of Medicine at OSU. Dr. Afzali holds the Abercrombie & Fitch Endowed Chair in Inflammatory Bowel Disease. She received her medical degree and then completed an Internal Medicine residency and Gastroenterology fellowship at the University of Washington in Seattle, WA. While in fellowship, Dr. Afzali worked in outcomes research and epidemiology, and also graduated with a Master’s in Public Health. Her sub-specialty training includes a one-year advanced IBD fellowship at the University of Washington, prior to becoming faculty. While practicing at the University of Washington – Harborview Medical Center, Dr. Afzali served as the Director of the IBD Program and Associate Medical Director of Gastroenterology Clinics at The Ohio State University. Her research interests include clinical outcomes and association of bowel and joint disease, the influence of the metabolic syndrome and impact of race/ethnicity in IBD, as well as pharmacoeconomics, pediatric-to-adult transition, and women of childbearing age with IBD. She is also extensively involved in IBD clinical trials for investigational therapies. She has extensive peer-reviewed publications, an invited lecturer on national and international programs, and serves on several international advisory boards and committees including Co-Chair of the Crohn’s & Colitis National Professional Education Committee and Member of the ACG Minority Affairs and Cultural Diversity Committee.
Rajeev Jain, MD
Rajeev Jain, MD
Board Certified Gastroenterologist, Chief of Gastroenterology, Texas Digestive Disease Consultants
I choose to specialize in gastroenterology as this specialty blends the needs for diagnostic reasoning with procedural interventions across a broad variety of symptoms and disorders. I am interested in colon cancer screenings, heartburn, Barrett’s esophagus, and inflammatory bowel disease. Studied at: Undergrad: University of Texas at Austin, Medical School: Baylor College of Medicine, Residency in Internal Medicine and Fellowship in Gastroenterology: University of Texas Southwestern Medical School. Certifications Held: Board Certified in Gastroenterology. I am a Fellow of the American College of Physicians, American Gastroenterological Association, and American Society of Gastrointestinal Endoscopy. I have been named annually to D Magazine “Best Doctors” in Dallas since 2001. In 2002, I was appointed as Chief of Gastroenterology at Texas Health Presbyterian Hospital. Since 2006, I have been annually named a Texas Monthly Super Doctor. I received the Presbyterian Hospital House Staff Annual Robert L. North, M.D. Teaching Award for 2002-2003. In December 2012, I was presented the Outstanding Contribution in the Field of Medicine award by the Greater Dallas Indo-American Chamber of Commerce. I served on the Texas Society for Gastrointestinal Endoscopy as a Councilor from 2013-2015. I serve on the Governing Board of the American Gastroenterological Association as Clinical Practice Councillor from 2015-2017, as well as on the Board of Directors for the American Board of Internal Medicine from 2016-2018.
Scott Lee
Scott Lee
Associate Professor of Medicine
Dr. Lee is an associate professor of medicine with expertise in inflammatory bowel disease (Crohn’s disease and ulcerative colitis). Dr. Lee earned his bachelor’s degree at Pomona College and his M.D. at Jefferson Medical College. He completed his residency in internal medicine at the University of Colorado in Denver. After residency, Dr. Lee completed his gastroenterology fellowship at the University of Washington. After completing his fellowship, he attended the University of Chicago and Cedar-Sinai in Los Angeles as a visiting physician to gain additional training in IBD. Since finishing his fellowship, he has been an attending gastroenterology physician at the University of Washington Medical Center. Currently his clinical practice is at the Digestive Disease Center at the University of Washington and is dedicated exclusively to providing care to patients with the diagnosis of IBD. His research is focused on inflammatory bowel diseases (IBD) including – new therapies for IBD, improving outcomes in the treatment and long term management of IBD, evaluation of non-invasive biomarkers to assess disease activity in IBD patients and the effects of the microbiome on IBD. He has participated in more than 100 clinical trials in IBD and continues to have an active clinical research program. He is a member of the Crohn’s Colitis Foundation of America (CCFA), American Gastroenterology Association, American College of Gastroenterology and American Society of Gastrointestinal Endoscopy. He is a past chair of Northwest CCFA Chapter Medical Advisory Committee (CMAC) and continues as a current member of the CMAC.
Feza Remzi, MD
Feza Remzi, MD
Colorectal Surgeon at NYU Langone, Director of IBD Center, Professor of Surgery at NYU School of Medicine
As a colorectal surgeon at NYU Langone, Dr. Remzi is a foremost expert in the surgical management of Inflammatory Bowel Disease, also known as Crohn’s Disease and Ulcerative Colitis. Dr. Remzi performs pelvic pouch surgery and complex abdominopelvic re-operative surgery, as well as sphincter-saving surgery for rectal cancer, applying minimally invasive techniques to manage colorectal conditions. Dr. Remzi serves as the director of the Inflammatory Bowel Disease Center and is one of the few colorectal surgeons in the world who is specialized in caring for people who are experiencing problems with a prior pelvic pouch, or J-pouch, procedures. He states "I have been humbled and privileged to be able to help my patients for more than 20 years. I treat my patients the way I would treat my own family. I take a team approach to care, so we bring together medical, surgical, and nursing professionals who devote 100 percent of their efforts to giving patients a better chance at life. Many of the people I treat are experiencing complex problems that impact not only their own quality of life but also that of their families. Therefore, I include patients’ family members as a part of the treatment team." As a national and international expert in colorectal surgery, Dr. Remzi has published many articles and book chapters on the surgical management of Inflammatory Bowel Disease, ileal J-pouch surgery, and re-operative abdominopelvic surgery. He is an honored member of the American Surgical Association and is humbled to be one of only a handful of surgeons in the world who is a member of the International Organization For the Study of Inflammatory Bowel Disease.
Tina Ha, MD
Tina Ha, MD
Director, Inflammatory Bowel Diseases Section, Mayo Clinic Arizona
Dr. Tina Ha is a gastroenterologist in Scottsdale, Arizona. She is affiliated with multiple hospitals, including Mayo Clinic- Phoenix, where she is the Director of the Inflammatory Bowel Diseases Section, and Cedars-Sinai Medical Center. Dr. Ha earned her medical degree from the Albert Einstein College of Medicine of Yeshiva University. She did an internal medicine residency at Washington University in St. Louis School of Medicine as well as a fellowship in gastroenterology. She continued to a fellowship in inflammatory bowel disease at the Icahn School of Medicine at Mount Sinai. She likes to spend her free time exploring with her golden retriever Sebastian, - who does not enjoy walking or retrieving, friends and family. Dr. Ha has contributed to many publications on the topic of IBD.
Gary Lichtenstein, MD
Gary Lichtenstein, MD
Director, Inflammatory Bowel Disease Center, Professor of Medicine, University of Pennsylvania
Gary R. Lichtenstein, MD, FACP, FACG, AGAF is the Director of the Inflammatory Bowel Disease Center and a Professor of Medicine in the Gastrointestinal Division of the Department of Medicine at the Hospital of the University of Pennsylvania and the University of Pennsylvania School of Medicine in Philadelphia, Pennsylvania. Dr. Lichtenstein earned his medical degree from the Mount Sinai School of Medicine, in New York, New York. He then completed his internship and residency in Internal Medicine at Duke University Medical Center, in Durham, North Carolina. He also served a fellowship in Gastroenterology at the Hospital of the University of Pennsylvania of the University Of Pennsylvania School Of Medicine. His current research interests encompass investigational therapies for the treatment of ulcerative colitis and Crohn's disease. Dr. Lichtenstein has received numerous research grants focusing on these areas and has served as the national/ international principal investigator evaluating novel agents for therapeutic trials in the treatment of Ulcerative Colitis and Crohn's disease.
Bincy Abraham, MD
Bincy Abraham, MD
Director, Fondren IBD Program, Director, Gastroenterology Fellowship Program Underwood Center for Digestive Disorders, Houston Methodist Hospital
Bincy P Abraham, MD, MS, AGAF, FACG is the Distinguished Professor and Director of the Fondren Inflammatory Bowel Disease Program at the Underwood Digestive Diseases Center of Houston Methodist Hospital. She is also the Program Director for the Gastroenterology Fellowship at Houston Methodist Hospital. Dr. Abraham earned her undergraduate degree in bioengineering at Texas A&M University in College Station, and then received her medical degree from the University of Texas Medical Branch (UTMB) in Galveston. She completed her internal medicine internship and residency, as well as a gastroenterology fellowship at UTMB, where she also earned a master’s in clinical investigation and received specialized training in inflammatory bowel disease (IBD). During her training, she completed a National Visiting Fellow IBD Rotation Program through the Crohn’s and Colitis Foundation of America at Cedars-Sinai Medical Center in Los Angeles, California. After fellowship, she joined as faculty as assistant professor of medicine in the section of Gastroenterology and Hepatology at Baylor College of Medicine where she served as director of the Baylor Clinic Inflammatory Bowel Disease Center for over 5 years before her move to Houston Methodist Hospital. She is board-certified in Internal medicine and Gastroenterology. Her particular interest in inflammatory bowel disease includes the transition of adolescent IBD patients from pediatric to adult care as well as women’s issues and pregnancy in IBD. She chairs the Southern Regional Chapter of the CCFA Medical Advisory Committee, has served as president of the Texas Gulf Coast Gastroenterology Society, co-directed the Texas Society of Gastroenterology & Endoscopy Annual meeting, is involved in national committees for American College of Gastroenterology, and member of American Gastroenterology Association, and Crohn's and Colitis Foundation.
Brian Feagan, MD, MSc
Brian Feagan, MD, MSc
Professor of Medicine at the Schulich School of Medicine & Dentistry in London, Ontario, Senior Scientific Director of Alimentiv Inc
Dr. Brian Feagan is a gastroenterologist, with training in Clinical Epidemiology and Biostatistics. His research focus is the design, conduct, and execution of large-scale randomized controlled trials (RCTs) in Crohn’s disease (CD) and ulcerative colitis (UC), and over the past 30 years, has been Principal Investigator in over 140 multi-center RCTs. His research has been devoted to the development, validation, and optimization of outcome measures to assess the efficacy of novel therapeutics in CD and UC. Dr. Feagan is Professor of Medicine at the Schulich School of Medicine & Dentistry, a gastroenterologist at London Health Sciences Centre and Senior Scientific Director of Alimentiv Inc (formerly Robarts Clinical Trials Inc). Brian G. Feagan completed a medical degree at the University of Western Ontario in London, Ontario, Canada. His postdoctoral training included a residency in the Department of Medicine and a fellowship in Gastroenterology at the University of Western Ontario. A Fellow of the Royal College of Physicians and Surgeons of Canada, Dr. Feagan holds membership in the Canadian and American Association of Gastroenterology, the American College of Gastroenterology, the College of Physicians and Surgeons of Ontario, Crohn’s and Colitis Canada (CCC), and the European Crohn’s & Colitis Organization (ECCO). He is the recipient of the 2013 Senior Achievement Award from the Crohn’s & Colitis Foundation of America (CCFA) and the Dean’s Award of Excellence in 2013 from the University of Western Ontario. He has authored over 200 articles, book chapters and has also given over 900 invited presentations, at national and international scientific meetings. In 1997, Dr. Feagan became Director of Robarts Clinical Trials (now Alimentiv, Inc.).
  • Accreditation:

    1st IBDHorizons Gulf Coast Symposium

    Course Information
    1 day - multiplatform meeting for in-person & virtual participation covering Louisiana and the surrounding region with an estimated 200 attendees. An exclusively virtual conference platform will be offered if an in-person meeting cannot be safely conducted.

    Intended Audience
    This activity was developed for healthcare providers caring for IBD patients, including gastroenterologists, surgeons, gastroenterology nurses, advanced nurse practitioners, physician assistants, and pharmacists.

    Learning Objectives
    At the conclusion of this learning activity, participants will do the following:

    1. Recognize the particular challenges related to fertility, pregnancy, prenatal and postnatal care in IBD and review the latest recommendations.
    2. Describe the comparative efficacy of the currently available therapies and the rationale for optimal positioning of these agents in IBD today.
    3. Recognize the various medical and surgical challenges for patients who receive an ileoanal pouch and the latest management recommendations.
    4. Assess the latest evidence regarding the role of therapeutic drug monitoring, proactive and reactive, to optimize response to biologic therapy in patients with IBD.
    5. Describe the clinical presentation of Crohn’s disease patients with strictures and discuss the best management for strictures including surgical intervention, endoscopic management and medical treatments.
    6. Recognize the postoperative clinical course for IBD patients who undergo surgery and review the medical and surgical challenges and their optimal management.
    7. Apply up-to-date practice in managing dysplasia in IBD from detection to endoscopic and surgical intervention.
    8. Discuss the newly approved and soon to be approved biologic and non-biologic therapies for IBD, including the risks, efficacy, and special considerations when utilizing these therapies.

     

    Accreditation and Certification

    In support of improving patient care, this activity has been planned and implemented by the Annenberg Center for Health Sciences at Eisenhower (Annenberg Center) and IBDHorizons. The Annenberg Center for Health Sciences at Eisenhower is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

    Physicians
    The Annenberg Center for Health Sciences at Eisenhower designates this live activity for a maximum of 6.0 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

    Nurses
    The Annenberg Center designates this live activity for a maximum of 6.0 American Nurses Credentialing Center (ANCC) contact hour, which includes 1.50 hours of pharmacology credit.

    Pharmacists

    This activity is designated for up to 6.0 contact hours (0.6 CEUs) of continuing pharmacy credit. Credit will be provided to the NABP CPE Monitor within 60 days after the activity completion.

    Disclosure Statement
    All individuals in control of the content of continuing education activities provided by the Annenberg Center are required to disclose to the audience all relevant financial relationships related to the content of the activity. Full disclosure of all relevant financial relationships will be made in writing to the audience prior to the activity.

    The ideas and opinions presented in this educational activity are those of the faculty and do not necessarily reflect the views of the Annenberg Center and/or its agents. As in all educational activities, we encourage practitioners to use their own judgment in treating and addressing the needs of each individual patient, taking into account that patient's unique clinical situation. The Annenberg Center disclaims all liability and cannot be held responsible for any problems that may arise from participating in this activity or following treatment recommendations presented.

    All staff at the Annenberg Center for Health Sciences at Eisenhower and IBDHorizons have no relationships to disclose.

    All of the relevant financial relationships listed for these individuals have been mitigated.

    This activity is supported by educational grants from AbbVie, Bristol Myers Squibb, Ferring Pharmaceuticals, Inc., Janssen Biotech, Inc., administered by Janssen Scientific Affairs, LLC, Pfizer, and Takeda Pharmaceuticals USA, Inc.

    IBDHorizons Privacy Policy
    https://ibdhorizons.com/privacy-policy/

    Annenberg Center for Health Sciences Privacy Policy
    Annenberg Center for Health Sciences Privacy Policy: Annenberg Center for Health Sciences respects your privacy. We don’t share information you give us or have the need to share this information in the normal course of providing the services and information you may request. If there should be a need or request to share this information, we will do so only with your explicit permission. See Privacy Statement and other information at https://annenberg.net/pages/privacyPolicy.php

  • Disclosure Statements: https://ibdhorizons.com/wp-content/uploads/2022/10/Disclosure-Statements_Gulf-Coast.pdf
QR Code

Leave a Reply

Your email address will not be published. Required fields are marked *

Thank you!

Success! We have received your activity evaluation and application for credit.

When can I expect my credit? Please allow 4-6 weeks from the date of the event for processing.

Who will I hear from? The Annenberg Center for Health Sciences at Eisenhower processes certificates and will email you once the certificate is issued.

Will they email my certificate directly? No, they will email you instructions to download the certificate from their site.

What do I do when the certificate is ready?

Your credit certificates will be stored on the website of our accrediting partner (annenberg.net)

  • Use this email from your evaluations, to create an account at Annenberg.net
  • If you already have an account, select Log In and reset your password
    • Once Logged in
      • Select Profile
      • Then proceed to My Courses
      • Go to Transcript and/or print your Certificate

REMINDER

Our team will not have copies of your certificates

Your certificates are linked to the email address provided on the evaluation forms.

Certificates are issued 4-6 weeks after an event

Your submission has been received!

We appreciate your submission into the Research Plenary Session at the 7th Annual IBDHorizons Pacific Northwest Symposium. The program committee looks forward to reviewing each submission carefully.  The team will notify about decisions by February 28, 2022 via email. Please check that you received a confirmation email.

For the winners, we are excited to hear your abstracts presented during the 7th Pacific Northwest Symposium on Saturday, March 5, 2022 at the Hyatt Regency Seattle. Further details will be provided by email. Thank you again and don’t forget to register!

Your submission has been received!

We appreciate your submission into the Research Plenary Session at the 5th Annual IBDHorizons Midwest Symposium. The program committee looks forward to reviewing each submission carefully.  The team will notify about decisions by January 20, 2022 via email. Please check that you received a confirmation email.

For the winners, we are excited to hear your abstracts presented during the 5th Midwest Symposium on Saturday, February 12, 2022 at the Hilton Columbus Downtown. Further details will be provided by email. Thank you again and don’t forget to register!